Travera

Travera is using a groundbreaking single-cell measurement technology developed at MIT to evaluate the ex vivo growth response of live tumor cells to potential candidate drugs. Traditionally, this process focused on measuring cell death and took over a week to get results. Travera is addressing this with their Rapid Therapy Selection test which measures the cell weight in response to cancer drugs which occurs in a matter of hours instead of days. Preliminary studies have shown this test works across 90% of cancers with different candidate drugs of varying mechanisms of action. Travera is overcoming biological and clinical barriers for better personalized cancer therapy.

Jobs: